Meibomian gland dysfunction
Conditions
Interventions
control group:The control group was treated with hot compress and 0.1% sodium hyaluronate eye drops. tid
Experimental group:Compared with the control group, 0.05% cyclosporine eye drops were added. bid
Sponsors
Suzhou Lixiang Eye Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years old; 2. There are symptoms in the eyes: dryness, pain, foreign body sensation, burning sensation, itching, fatigue, increased secretion and other symptoms; 3. One of the following changes in the eyelid margin: congestion of the eyelid margin, irregularity or thickening of the eyelid margin, obstruction of the opening of the meibomian gland or formation of a fat plug, and displacement of the opening of the meibomian gland; 4. Willing to cooperate in completing all the evaluation and follow-up of this trial; 5. Sign the written informed consent.
Exclusion criteria
Exclusion criteria: 1. Ocular factors: there are uncontrolled conjunctivitis, keratitis, uveitis and other eye diseases; history of eye surgery and trauma; 2. Complicated with systemic diseases: including Parkinson's disease, systemic lupus erythematosus, diseases affecting the secretion of sebaceous glands (such as atopic dermatitis, seborrheic dermatitis, rosacea, etc.), cardiac and renal insufficiency, hypertension and other diseases, pregnant women; 3. Medication history: excluding those who used other ophthalmic drugs within 2 weeks before enrollment, or those who had used cyclosporine eye drops.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ocular surface disease index, OSDI;Tear break up time, TBUT;Schirmer test;tear meniscus height, TMH;Meibomian gland excretion ability score;Levels of inflammatory factors IL-1 and PGE2 in tears; | — |
Countries
China
Contacts
Public ContactZhu Manhui
Suzhou Lixiang Eye Hospital
Outcome results
None listed